This is a preview of subscription content, log in via an institution to check access.
Reference
Marchetti M, et al. Is Idelalisib Cost-Effective for Refractory/Relapsed Chronic Lymphocytic Leukemia? a Decision Analysis in the Second-Line Setting. 57th Annual Meeting and Exposition of the American Society of Hematology : abstr. 3305, 5 Dec 2015. Available from: URL: https://ash.confex.com/ash/2015/webprogram/Paper82565.html
Rights and permissions
About this article
Cite this article
Idelalisib + rituximab good value for relapsed/refractory CLL. PharmacoEcon Outcomes News 745, 17 (2016). https://doi.org/10.1007/s40274-016-2758-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-016-2758-1